Gerresheimer serve biotech customers throughout the complete value chain and drug lifecycle management – from preclinical development work onwards.
Just-Evotec Biologics, a Contract Development and Manufacturing Organisation (CDMO), has announced an expansion of its development and manufacturing agreement with ABL. The partnership is set to enhance the production of broadly neutralising antibodies against HIV, marking a significant stride in
Jazz Pharmaceuticals has made a strategic move in the pharmaceutical industry by entering into a definitive agreement with Redx Pharma. This agreement involves the acquisition of global rights to the KRAS inhibitor program, a significant development in the field of contract
Samsung Biologics, a global contract development and manufacturing organisation (CDMO), has entered into a strategic partnership with LegoChem Biosciences, a biotech company at the forefront of the research and development of antibody-drug conjugate (ADC) programs. This partnership was announced on February 7,
Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced on January 23, 2024, that it will perform analytical release testing services on the world’s first CRISPR/Cas9 genome-edited cell therapy. The announcement was made from the company’s headquarters in
BioNTech, a next-generation immunotherapy company, and Autolus Therapeutics, a clinical-stage biopharmaceutical company, announced a strategic collaboration on February 8, 2024. The collaboration aims to advance both companies’ autologous CAR-T programs towards commercialisation, pending regulatory authorisations. The strategic alliance leverages manufacturing and
Fresenius Mabxience has announced a Contract Development and Manufacturing Organisation (CDMO) agreement with Biosidus. This collaboration aims to develop a treatment for Fabry disease, a rare genetic disorder. The use of Agalsidase Beta is an innovative treatment for Fabry disease. This
Lonza and Oxford Nanopore Technologies have announced a collaboration to cGMP validate and commercialise a novel test to accelerate the analysis of mRNA products. The announcement was made on Tuesday, 30th January 2024. The partnership aims to enable advanced and innovative analysis for multiple
Societal CDMO is a contract development and manufacturing organisation (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, and Benuvia Operations, LLC, a U.S.-based drug developer and manufacturer of active pharmaceutical ingredients (APIs) with
Agilent, a laboratory technologies company has announced a collaboration with Incyte, a renowned biopharmaceutical company. The partnership aims to develop Companion Diagnostics (CDx) in the fields of hematology and oncology. The collaboration between Agilent and Incyte marks a significant step
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
